How the ESRRB protein influences glioblastoma growth and spread
Novel functions of ESRRB in glioblastoma
This project tests whether changing a specific form of the ESRRB protein can make glioblastoma cells die and stop spreading, with the goal of helping people with this aggressive brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11258513 on NIH RePORTER |
What this research studies
Researchers will study how alternative splicing creates a beta2 form of the ESRRB protein and how that form acts in glioblastoma cells. They will use lab-grown tumor cells and molecular tools to change splicing factors like SRSF6, activate beta2 with a drug called DY131, and watch effects on cell survival, movement, and treatment resistance. The team will examine how beta2 interacts with the actin-binding protein cortactin to control tumor cell motility. Results may identify new targets or drugs to reduce tumor invasion and improve responses to existing therapies.
Who could benefit from this research
Good fit: The findings would be most relevant to adults with glioblastoma, especially those whose tumors show ESRRB expression or signs of altered splicing.
Not a fit: People without glioblastoma or whose tumors do not show ESRRB or related splicing changes are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could point to new treatments that make glioblastoma cells more likely to die and less able to invade the brain, potentially improving survival and slowing recurrence.
How similar studies have performed: Early laboratory studies have shown that activating the ESRRB beta2 isoform with the drug DY131 can trigger glioblastoma cell death and reduce cell movement, but patient benefit has not yet been demonstrated.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Riggins, Rebecca B — Georgetown University
- Study coordinator: Riggins, Rebecca B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.